Literature DB >> 22378279

High prevalence of genetic variants previously associated with LQT syndrome in new exome data.

Lena Refsgaard1, Anders G Holst, Golnaz Sadjadieh, Stig Haunsø, Jonas B Nielsen, Morten S Olesen.   

Abstract

To date, hundreds of variants in 13 genes have been associated with long QT syndrome (LQTS). The prevalence of LQTS is estimated to be between 1:2000 and 1:5000. The knowledge of genetic variation in the general population has until recently been limited, but newly published data from NHLBI GO Exome Sequencing Project (ESP) has provided important knowledge on this topic. We aimed to investigate the prevalence of previously LQTS-associated variants in ESP (5400 individuals), in order to identify possible false-positive LQTS variants. With this aim, we performed a search for previously published LQTS-associated variants in ESP. In addition, a PolyPhen-2 prediction was conducted, and the four most prevalent LQTS-associated variants with significant functional effects present in ESP were genotyped in a second control population. We identified 33 missense variants previously associated with LQTS in ESP. These 33 variants affected 173 alleles and this corresponded to a LQTS prevalence of 1:31 in the ESP population. PolyPhen-2 predicted 30% of the 33 variants present in ESP to be benign compared with 13% among LQTS-associated variants not present in ESP (P=0.019). Genotyping of the four variants KCNH2 P347S; SCN5A: S216L, V1951L; and CAV3 T78M in the control population (n=704) revealed prevalences comparable to those of ESP. Thus, we identified a much higher prevalence of previously LQTS-associated variants than expected in exome data from population studies. Great caution regarding the possible disease causation of some of these variants has to be taken, especially when used for risk stratification in family members.

Entities:  

Mesh:

Year:  2012        PMID: 22378279      PMCID: PMC3400735          DOI: 10.1038/ejhg.2012.23

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


Introduction

Congenital long QT syndrome (LQTS) is an inherited cardiac disorder characterised by a prolonged QT interval on the electrocardiogram and sudden cardiac death secondary to cardiac arrhythmias. The prevalence of LQTS in the general population has been estimated to be between 1:2000 and 1:5000.[1] In most cases, LQTS is considered a monogenic disorder, and to date hundreds of variants in 13 genes have been associated with this syndrome.[1, 2] However, variants previously reported to be causative in LQTS have subsequently been shown to be rare variants with only a modest disease-modifying effect or even non-pathogenic.[3] Until recently, there has only been limited knowledge regarding the genetic variation in the general population, especially with regards to low-frequency variants. This was changed in June 2011, when whole exome data from the NHLBI GO Exome Sequencing Project (ESP) was published.[4] In order to identify possible false-positive LQTS variants reported in the literature, we aimed to investigate the prevalence of previously LQTS-associated variants in new ESP exome data and compare the prevalence of these variants with the expected prevalence of LQTS in the same population.

Methods

In ESP, next-generation sequencing of all protein-coding regions in 5400 persons from different population studies were carried out.[4] No clinical data were available on the ESP population, nor at request. By literature search, we found inclusion- and exclusion criteria of 9 out of 12 populations used in ESP. None of these have specifically included persons with channelopathies or other heart diseases and at least two cohorts have excluded such patients. ESP exome data were systematically searched for previously published missense and nonsense LQTS-associated variants reported in a recent comprehensive review by Hedley et al[1] and in data from the The Human Gene Mutation Database (HGMD).[5] In addition, we have included the recently published KCNJ5 variant reported by Yang et al,[2] in order to include all 13 genes so far associated with LQTS. Due to the lack of data regarding variants positioned in introns and UTR regions in ESP, these could not be included. The literature was searched for functional data and family co-segregation of all the previously identified LQTS-associated variants also identified in the ESP population. Co-segregation was defined as at least two family members both having the phenotype and the genotype. In addition, we conducted a PolyPhen-2 prediction on all previously reported LQTS-associated missense variants and compared protein damage predictions between LQTS-associated variants identified in ESP with those variants not identified in ESP.[6] Nonsense variants were assumed probably damaging. Differences in proportions of PolyPhen-2 predictions between groups were assessed using a Fisher's exact test. Furthermore, we genotyped (Sanger sequencing, as described previously[7]) variants with (1) convincing LQTS association in terms of significant functional effects on channel function and (2) a prevalence in ESP European American population high enough (≥7:5295) to have a reasonable chance to be detected in our own two independent healthy control populations (n=704) of Northern European origin with no history of arrhythmias or other cardiac diseases,[7, 8] and with available ECGs.

Results

In all, 33 out of 631 missense and nonsense variants previously associated with LQTS (5.2%) were found in the ESP population. All 33 variants were missense variants and affected 173 alleles. Thirteen of the variants were identified in three or more alleles. No nonsense variants were found. The previously LQTS-associated variants identified in the ESP population are listed in Table 1. On an average, the genes investigated in this study have been screened in 5298 individuals. If we assume that no individuals in the ESP population harbour more than one of the LQTS-associated variants and that all are heterozygote carriers, it corresponds to a LQTS genotype prevalence of 1:31 (173:5298). Thirteen variants were present in three or more alleles corresponding to a LQTS genotype prevalence of 1:37 (145:5298). Six variants associated with acquired/drug-induced LQTS were also identified in ESP; these variants were not included in the present analysis. Literature search regarding functional data and family co-segregation revealed that 19 of the 33 identified LQTS-associated variants have been investigated functionally and 16 of these did have functional effects, but there was a striking lack of data regarding family co-segregation (Table 1 and Supplementary Table).
Table 1

Variants associated with LQTS present in the ESP population

        Level of LQTS evidence
GeneVariantAmino acidTypeMinor alleleaTotal allelesaVariant associated withPolyPhen-2 resultsFamily co-segregationFunctional data
KCNQ1c.532G>AA178TMissense210 756LQT1bProbably damagingEquivocalNo data available
 c.613G>AV205MMissense110 756LQT1cProbably damagingYes, but incomplete penetranceLoss of function
 c.959C>AP320HMissense110 754LQT1cProbably damagingYesLoss of function
 c.1189C>TR397WMissense210 758LQT1bProbably damagingNo data availableNo data available
 c.1352G>AR451QMissense110 754LQT1cPossibly damagingNo data availableNo data available
 c.1354C>TR452WMissense210 754LQT1cProbably damagingNo data availableNo data available
 c.1576A>GK526EMissense210 758LQT1bProbably damagingNo data availableNo data available
 c.1831G>AD611NMissense310 716LQT1dPossibly damagingNo data availableNo data available
 c.1927G>AG643SMissense7910 528aLQTSdBenignYes, but incomplete penetranceLoss of function
          
KCNH2c.1039G>AP347SMissense710 758LQT2cBenignEquivocalLoss of function
 c.1912A>GK638EMissense110 732LQT2bProbably damagingNo data availableNo data available
 c.2653G>AR885CMissense110 758LQT2cProbably damagingNo data availableNo effect
 c.2660G>AR887HMissense110 758LQT2bProbably damagingNo data availableNo data available
 c.2948G>AT983IMissense310 740LQT2bProbably damagingNo data availableNo data available
          
SCN5Ac.647G>AS216LMissense1110 248LQT3dProbably damagingNo data availableGain of function
 c.1384G>AE462KMissense19966LQT3bProbably damagingNo data availableNo data available
 c.1715G>TA572DMissense1810 194sLQTScBenignNoGain of function
 c.1844C>TG615EMissense310 264diLQTScBenignNo data availableGain of function/no effect
 c.1852G>AL618FMissense2110 274diLQTSbProbably damagingNo data availableNo effect
 c.1855G>AL619FMissense110 262LQT3cBenignEquivocalGain of function
 c.2066G>AR689HMissense110 488LQT3bBenignNo data availableNo data available
 c.2074G>TQ692KMissense210 494LQT3cBenignNo data availableNo data available
 c.3578G>AR1193QMissense710 747aLQTSbBenignNo data availableGain of function
 c.3911G>AT1304MMissense510 384LQT3bProbably damagingYesGain of function
 c.5336C>TT1779MMissense110 758LQT3bProbably damagingNo data availableNo data available
 c.5360C>TS1787NMissense610 758LQT3bPossibly damagingNo data availableGain of function
 c.5711C>TS1904LMissense10 10 416LQT3dProbably damagingEquivocalGain of function
 c.5848C>AV1951LMissense1710 278LQT3dBenignNo data availableGain of function
 c.5873C>TR1958QMissense210 258LQT3bBenignNo data availableNo data available
 c.6016G>CP2006AMissense1210 108sLQTSbBenignYes, but incomplete penetranceGain of function
          
ANK2
          
KCNE1c.253C>TD85NMissense9410 758aLQTSbBenignNo data availableLoss of function
 c.325G>AV109IMissense210 758LQT5cBenignEquivocalLoss of function
          
KCNE2c.22A>GT8AMissense4810 758diLQTSbProbably damagingNo data availableLoss of function
 c.161T>CM54TMissense310 758LQT6dProbably damagingNo data availableLoss of function
 c.170T>CI57TMissense410 758LQT6dProbably damagingEquivocalNo effect/loss of function
 c.229C>TR77WMissense210 758LQT6cProbably damagingNo data availableNo effect
          
KCNJ2
CACNA1C
CAV3c.233C>TT78MMissense4610 758LQT9cProbably damagingNo data availableGain of function
SCN4B
AKAP9c.4709C>TS1570LMissense110 758LQT11dBenignYesLoss of function
SNTA1c.1169C>TA390VMissense110 758LQT12bPossibly damagingNo data availableGain of function
KCNJ5e

Abbreviations: aLQTS, acquired LQTS; diLQTS, drug-induced LQTS; sLQTS, suspected LQTS.

Data from NHLBI Exome Sequencing Project (ESP).[4]

Hedley et al[1] and HGMD.[5]

HGMD.[5]

Hedley et al.[1]

Yang et al.[2]

PolyPhen-2 analysis of the 33 LQTS variants predicted 19 (58%) to be probably damaging, 4 (12%) to be possibly damaging, and 10 (30%) were predicted to be benign (Table 1). Of the remaining 558 missense and 40 nonsense LQTS-associated variants, not present in ESP, 451 (75%) were predicted probably damaging, 69 (12%) possibly damaging, and 78 (13%) benign. This difference in the distribution of the three PolyPhen-2 categories among the two groups was statistically significant both for the overall comparison (P=0.027) and when comparing the categories benign (P=0.016) and probably damaging (P=0.038) independently. As no nonsense variants were found in ESP, a more conservative approach is to compare only the missense variants in the two groups; 558 missense LQTS-associated variants were not present in ESP and of these 411 (74%) were predicted probably damaging, 69 (12%) possibly damaging, and 78 (14%) benign. In this case, only a borderline significant difference was found (P=0.051) for the overall comparison. Four variants (KCNH2 P347S; SCN5A S216L, V1951L, and CAV3 T78M) were, based on our criteria, genotyped in our control populations (n=704), and this revealed variant prevalences comparable to those found in ESP (Table 2). One of the variant carriers harbouring CAV3 T78M had a QTc interval of 462 ms, but all other variant carriers had normal QTc intervals (QTc≤440 ms) including four other carriers of CAV3 T78M (Table 2).
Table 2

Allele frequencies in ESP and in control population

   MAF ESPMAF controls
GeneAmino acidrs#African-American (%)European-American (%)Total (%)Northern European (%)QTc interval (ms)
KCNH2P347Srs1387766840.000.100.070.14414, 436
SCN5AS216Lrs412765250.030.150.110.07400
 V1951Lrs413154930.380.060.170.07426
CAV3T78Mrs725466680.380.460.430.43410, 436, 462, 435, 412, RBBBa

Abbreviation: MAF, minor allele frequency.

Right bundle branch block, QTc estimate not possible.

Discussion

We identified 33 missense variants out of 631 (5.2%) variants previously associated with LQTS in the ESP data. These 33 variants correspond to a LQTS genotype prevalence of 1:31 in the ESP. If the prevalence of LQTS is set at 1:2000 (a high estimate), then we would expect only three persons in the ESP population to have LQTS. Thus, we found a very large overrepresentation of previously LQTS-associated variants in the ESP, indicating a very dubious LQTS association for these variants as a group. Of cause, we cannot exclude the possibility that there might be an overrepresentation of LQTS patients in the ESP population, although this seems unlikely, due to the size of the overrepresentation and the fact that ESP is based on population studies mainly representing the general population. Even if we had clinical data on all individuals, we could not make a significantly different conclusion due to the possibility of reduced penetrance of the variants. To test the possible overrepresentation of LQTS-associated variants in ESP we genotyped the four most prevalent LQTS-associated variants with significant functional effects present in ESP in two cohorts of healthy individuals with available ECGs.[7, 8] The four variants were present in our control population with prevalences consistent with those of ESP (Table 2). Thus, the present results indicate that overrepresentation of LQTS-associated variants does not seem to be a problem in ESP, but more importantly the results confirm that at least these four LQTS-associated variants with high prevalence in ESP and significant functional effects are not monogenic causes of LQTS. In addition, we did a PolyPhen-2 prediction both for the variants found in ESP and the ones we did not find. Of the 33 variants found in ESP, 30% were predicted to be benign compared with 13% among the variants not found in ESP (P=0.016). This further strengthens the argument that these variants are not disease causing. The majority of the variants have been shown to have functional effects in electrophysiological experiments performed in heterologous cell models. This suggests that they may have some pathological influence, but only a very small fraction of studies showed family co-segregation. Thirteen of the variants were present in three or more alleles in ESP, and thus it seems reasonable to assume that these variants are not monogenic causes of LQTS, as 1:37 are carriers of one of these variants. The remaining 20 variants are present in just one or two alleles in ESP and an interpretation of the pathogenicity of these variants are therefore much less straightforward. Taken together, the present results indicate that a large proportion of the 33 variants previously associated with LQTS but now identified in ESP are very unlikely to be monogenic causes of LQTS and are maybe just innocent bystanders. Others are likely to be variants with reduced penetrance, or in some cases disease modifiers. Thus, great caution must be taken regarding the possible disease causation of these variants when found in LQTS (Table 1). It is noteworthy, that 94.8% of the previously LQTS-associated variants were not present in ESP and thus the pathogenicity of the majority of these variants seems to be corroborated. Genetic screening has become an important tool in at least family examinations of LQTS. It is for this reason important that variants being associated with LQTS are truly disease causing. A patient with genuine LQTS but a false-positive variant result might have another true disease-causing variant that is not found and this could lead to misdiagnosis of family members with consequences for treatment, clinical advice, and follow-up.

Conclusion

In recently released exome data, we identified a much higher prevalence of previously LQTS-associated variants than expected based on the prevalence of LQTS in the general population. Our findings suggest that some of the previously associated LQTS variants are false-positive findings and that great caution must be taken regarding the possible disease causation of these variants, especially when used for risk stratification in family members.
  6 in total

1.  Mutations in sodium channel β-subunit SCN3B are associated with early-onset lone atrial fibrillation.

Authors:  Morten S Olesen; Thomas Jespersen; Jonas B Nielsen; Bo Liang; Daniel V Møller; Paula Hedley; Michael Christiansen; András Varró; Søren-Peter Olesen; Stig Haunsø; Nicole Schmitt; Jesper H Svendsen
Journal:  Cardiovasc Res       Date:  2010-11-04       Impact factor: 10.787

2.  A novel nonsense variant in Nav1.5 cofactor MOG1 eliminates its sodium current increasing effect and may increase the risk of arrhythmias.

Authors:  Morten S Olesen; Niels F Jensen; Anders G Holst; Jonas B Nielsen; Jacob Tfelt-Hansen; Thomas Jespersen; Ahmad Sajadieh; Stig Haunsø; Jens T Lund; Kirstine Calloe; Nicole Schmitt; Jesper Hastrup Svendsen
Journal:  Can J Cardiol       Date:  2011-05-28       Impact factor: 5.223

3.  Identification of a Kir3.4 mutation in congenital long QT syndrome.

Authors:  Yanzong Yang; Yiqing Yang; Bo Liang; Jinqiu Liu; Jun Li; Morten Grunnet; Søren-Peter Olesen; Hanne B Rasmussen; Patrick T Ellinor; Lianjun Gao; Xiaoping Lin; Li Li; Lei Wang; Junjie Xiao; Yi Liu; Ying Liu; Shulong Zhang; Dandan Liang; Luying Peng; Thomas Jespersen; Yi-Han Chen
Journal:  Am J Hum Genet       Date:  2010-06-11       Impact factor: 11.025

4.  Epidemiologic, molecular, and functional evidence suggest A572D-SCN5A should not be considered an independent LQT3-susceptibility mutation.

Authors:  David J Tester; Carmen Valdivia; Carole Harris-Kerr; Marielle Alders; Benjamin A Salisbury; Arthur A M Wilde; Jonathan C Makielski; Michael J Ackerman
Journal:  Heart Rhythm       Date:  2010-04-24       Impact factor: 6.343

5.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

Review 6.  The genetic basis of long QT and short QT syndromes: a mutation update.

Authors:  Paula L Hedley; Poul Jørgensen; Sarah Schlamowitz; Romilda Wangari; Johanna Moolman-Smook; Paul A Brink; Jørgen K Kanters; Valerie A Corfield; Michael Christiansen
Journal:  Hum Mutat       Date:  2009-11       Impact factor: 4.878

  6 in total
  59 in total

Review 1.  Genetic testing for inherited cardiac disease.

Authors:  Arthur A M Wilde; Elijah R Behr
Journal:  Nat Rev Cardiol       Date:  2013-07-30       Impact factor: 32.419

Review 2.  Genotype- and phenotype-guided management of congenital long QT syndrome.

Authors:  John R Giudicessi; Michael J Ackerman
Journal:  Curr Probl Cardiol       Date:  2013-10       Impact factor: 5.200

3.  Enhanced Classification of Brugada Syndrome-Associated and Long-QT Syndrome-Associated Genetic Variants in the SCN5A-Encoded Na(v)1.5 Cardiac Sodium Channel.

Authors:  Jamie D Kapplinger; John R Giudicessi; Dan Ye; David J Tester; Thomas E Callis; Carmen R Valdivia; Jonathan C Makielski; Arthur A Wilde; Michael J Ackerman
Journal:  Circ Cardiovasc Genet       Date:  2015-04-22

Review 4.  The current state of clinical interpretation of sequence variants.

Authors:  Derick C Hoskinson; Adrian M Dubuc; Heather Mason-Suares
Journal:  Curr Opin Genet Dev       Date:  2017-01-31       Impact factor: 5.578

Review 5.  Genetic Variation in Cardiomyopathy and Cardiovascular Disorders.

Authors:  Elizabeth M McNally; Megan J Puckelwartz
Journal:  Circ J       Date:  2015-06-04       Impact factor: 2.993

Review 6.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  Europace       Date:  2017-04-01       Impact factor: 5.214

7.  Next generation sequencing in cardiovascular diseases.

Authors:  Francesca Faita; Cecilia Vecoli; Ilenia Foffa; Maria Grazia Andreassi
Journal:  World J Cardiol       Date:  2012-10-26

8.  Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results.

Authors:  Holly K Tabor; Paul L Auer; Seema M Jamal; Jessica X Chong; Joon-Ho Yu; Adam S Gordon; Timothy A Graubert; Christopher J O'Donnell; Stephen S Rich; Deborah A Nickerson; Michael J Bamshad
Journal:  Am J Hum Genet       Date:  2014-07-31       Impact factor: 11.025

9.  Reclassification of Variants of Uncertain Significance in Children with Inherited Arrhythmia Syndromes is Predicted by Clinical Factors.

Authors:  Jeffrey S Bennett; Madison Bernhardt; Kim L McBride; Shalini C Reshmi; Erik Zmuda; Naomi J Kertesz; Vidu Garg; Sara Fitzgerald-Butt; Anna N Kamp
Journal:  Pediatr Cardiol       Date:  2019-09-18       Impact factor: 1.655

10.  Cardiac structural and sarcomere genes associated with cardiomyopathy exhibit marked intolerance of genetic variation.

Authors:  Stephen Pan; Colleen A Caleshu; Kyla E Dunn; Marcia J Foti; Maura K Moran; Oretunlewa Soyinka; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2012-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.